PIK3CA mutation status, progression and survival in advanced HR+/HER2- breast cancer: A meta-analysis of published clinical trials
Số trang: 11
Loại file: pdf
Dung lượng: 1.90 MB
Lượt xem: 15
Lượt tải: 0
Xem trước 2 trang đầu tiên của tài liệu này:
Thông tin tài liệu:
Approximately 40% of hormone receptor positive/human epidermal receptor 2 negative (HR+/HER2-) metastatic breast cancer (mBC) patients harbor phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) mutations. However, associations between PIK3CA mutation status and clinical outcomes among patients with HR+/HER2- mBC have been heterogeneous across clinical trials.
Tìm kiếm theo từ khóa liên quan:
BMC Cancer Hormone receptor positive Human epidermal receptor 2 negative Metastatic breast cancer Overall survival Progression-free survivalGợi ý tài liệu liên quan:
-
Differences between physician and patient preferences for cancer treatments: A systematic review
13 trang 171 0 0 -
6 trang 166 0 0
-
Immune checkpoint inhibitors and their impact on liver enzymes and attenuation
7 trang 142 0 0 -
2011–2021 rising prevalence of HPV infection among oropharyngeal carcinoma in France
9 trang 118 0 0 -
12 trang 93 0 0
-
19 trang 74 0 0
-
17 trang 64 0 0
-
9 trang 43 0 0
-
12 trang 38 0 0
-
Investigating the prognostic and predictive value of the type II cystatin genes in gastric cancer
17 trang 37 0 0